Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.85
REGN's Cash-to-Debt is ranked lower than
71% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. REGN: 1.85 )
Ranked among companies with meaningful Cash-to-Debt only.
REGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.57  Med: 2.17 Max: No Debt
Current: 1.85
Equity-to-Asset 0.62
REGN's Equity-to-Asset is ranked lower than
53% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. REGN: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
REGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.64 Max: 0.95
Current: 0.62
0.18
0.95
Interest Coverage 107.75
REGN's Interest Coverage is ranked lower than
70% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 107.75 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 22.05 Max: 184.95
Current: 107.75
10.1
184.95
Piotroski F-Score: 4
Altman Z-Score: 11.81
Beneish M-Score: -3.01
WACC vs ROIC
11.59%
26.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 28.76
REGN's Operating Margin % is ranked higher than
90% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. REGN: 28.76 )
Ranked among companies with meaningful Operating Margin % only.
REGN' s Operating Margin % Range Over the Past 10 Years
Min: -91.55  Med: 3.92 Max: 35.3
Current: 28.76
-91.55
35.3
Net Margin % 19.34
REGN's Net Margin % is ranked higher than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. REGN: 19.34 )
Ranked among companies with meaningful Net Margin % only.
REGN' s Net Margin % Range Over the Past 10 Years
Min: -84.46  Med: -2.95 Max: 54.43
Current: 19.34
-84.46
54.43
ROE % 22.24
REGN's ROE % is ranked higher than
93% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. REGN: 22.24 )
Ranked among companies with meaningful ROE % only.
REGN' s ROE % Range Over the Past 10 Years
Min: -43.76  Med: -0.78 Max: 86.68
Current: 22.24
-43.76
86.68
ROA % 14.28
REGN's ROA % is ranked higher than
93% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. REGN: 14.28 )
Ranked among companies with meaningful ROA % only.
REGN' s ROA % Range Over the Past 10 Years
Min: -18.38  Med: 0.35 Max: 44.08
Current: 14.28
-18.38
44.08
ROC (Joel Greenblatt) % 46.79
REGN's ROC (Joel Greenblatt) % is ranked higher than
91% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. REGN: 46.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
REGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -173.81  Med: 7.5 Max: 61.97
Current: 46.79
-173.81
61.97
3-Year Revenue Growth Rate 30.20
REGN's 3-Year Revenue Growth Rate is ranked higher than
78% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. REGN: 30.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
REGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25  Med: 24.1 Max: 81.1
Current: 30.2
-25
81.1
3-Year EBITDA Growth Rate 20.70
REGN's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. REGN: 20.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
REGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.7  Med: 22.7 Max: 122.8
Current: 20.7
-56.7
122.8
3-Year EPS without NRI Growth Rate 27.40
REGN's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. REGN: 27.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
REGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.3  Med: -5.8 Max: 86.3
Current: 27.4
-38.3
86.3
GuruFocus has detected 4 Warning Signs with Regeneron Pharmaceuticals Inc $REGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» REGN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

REGN Guru Trades in Q2 2016

Paul Tudor Jones 2,956 sh (New)
Joel Greenblatt 30,151 sh (+1094.10%)
Vanguard Health Care Fund 3,279,190 sh (+3.46%)
Ken Fisher 613 sh (unchged)
Steven Cohen Sold Out
Ray Dalio Sold Out
Ron Baron 4,987 sh (-0.48%)
Mario Gabelli 1,329 sh (-1.04%)
Jim Simons 210,762 sh (-2.86%)
Frank Sands 2,659,741 sh (-21.49%)
Eaton Vance Worldwide Health Sciences Fund 108,200 sh (-21.02%)
» More
Q3 2016

REGN Guru Trades in Q3 2016

George Soros 1,381 sh (New)
Paul Tudor Jones 4,608 sh (+55.89%)
Ken Fisher 620 sh (+1.14%)
Vanguard Health Care Fund 3,279,190 sh (unchged)
Jim Simons Sold Out
Ron Baron 4,924 sh (-1.26%)
Frank Sands 2,497,378 sh (-6.10%)
Joel Greenblatt 24,745 sh (-17.93%)
Mario Gabelli 529 sh (-60.20%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (-43.94%)
» More
Q4 2016

REGN Guru Trades in Q4 2016

Jim Simons 250,560 sh (New)
Manning & Napier Advisors, Inc 440,316 sh (New)
Ken Fisher 715 sh (+15.32%)
Vanguard Health Care Fund 3,309,690 sh (+0.93%)
Ron Baron 4,969 sh (+0.91%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (unchged)
Mario Gabelli Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Frank Sands 2,302,802 sh (-7.79%)
Joel Greenblatt 12,096 sh (-51.12%)
» More
Q1 2017

REGN Guru Trades in Q1 2017

Paul Tudor Jones 600 sh (New)
Steven Cohen 70,000 sh (New)
Ron Baron 6,429 sh (+29.38%)
Frank Sands 2,933,444 sh (+27.39%)
Ken Fisher 806 sh (+12.73%)
Vanguard Health Care Fund 3,635,985 sh (+9.86%)
Joel Greenblatt Sold Out
Jim Simons 232,076 sh (-7.38%)
Manning & Napier Advisors, Inc 376,003 sh (-14.61%)
Eaton Vance Worldwide Health Sciences Fund 45,415 sh (-25.13%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CSLLY, NAS:BIIB, OTCPK:SHPGF, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:ALXN, OTCPK:GIKLY, OTCPK:UCBJY, NAS:BMRN, OTCPK:NVZMF, OTCPK:GMXAY, NAS:GILD, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:ALNY, NAS:BIVV, NAS:EXEL » details
Traded in other countries:REGN.Austria, RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Headquarter Location:USA
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has four marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; and Arcalyst in CAPS. Regeneron is also developing monoclonal antibodies with Sanofi in rheumatoid arthritis, atopic dermatitis, asthma, and cancer.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals - May 23, 2016

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron Science Talent Search to Ring The Nasdaq Stock Market Closing Bell
Manning & Napier’s Top 3 New Holdings Firm invested in wide array of industries in the 4th quarter
Manning & Napier Advisors Inc. acquired 35 new holdings during the final quarter of 2016. The firm’s top three new holdings are Bristol-Myers Squibb Co. (NYSE:BMY), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Campbell Soup Co. (NYSE:CPB). Read more...

Ratios

vs
industry
vs
history
PE Ratio 54.84
REGN's PE Ratio is ranked lower than
72% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. REGN: 54.84 )
Ranked among companies with meaningful PE Ratio only.
REGN' s PE Ratio Range Over the Past 10 Years
Min: 22.84  Med: 73.25 Max: 169.6
Current: 54.84
22.84
169.6
Forward PE Ratio 35.21
REGN's Forward PE Ratio is ranked lower than
74% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. REGN: 35.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 54.84
REGN's PE Ratio without NRI is ranked lower than
72% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. REGN: 54.84 )
Ranked among companies with meaningful PE Ratio without NRI only.
REGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.84  Med: 73.25 Max: 169.6
Current: 54.84
22.84
169.6
Price-to-Owner-Earnings 58.74
REGN's Price-to-Owner-Earnings is ranked lower than
73% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. REGN: 58.74 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
REGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 47.71  Med: 102.33 Max: 1511.41
Current: 58.74
47.71
1511.41
PB Ratio 9.95
REGN's PB Ratio is ranked lower than
83% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. REGN: 9.95 )
Ranked among companies with meaningful PB Ratio only.
REGN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.85 Max: 26.41
Current: 9.95
2.47
26.41
PS Ratio 10.61
REGN's PS Ratio is ranked higher than
57% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. REGN: 10.61 )
Ranked among companies with meaningful PS Ratio only.
REGN' s PS Ratio Range Over the Past 10 Years
Min: 3.69  Med: 12.29 Max: 28.22
Current: 10.61
3.69
28.22
Price-to-Free-Cash-Flow 39.86
REGN's Price-to-Free-Cash-Flow is ranked lower than
68% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. REGN: 39.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
REGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 32.37  Med: 92.05 Max: 1910.91
Current: 39.86
32.37
1910.91
Price-to-Operating-Cash-Flow 29.62
REGN's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. REGN: 29.62 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
REGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.64  Med: 50.78 Max: 559.41
Current: 29.62
21.64
559.41
EV-to-EBIT 33.05
REGN's EV-to-EBIT is ranked lower than
63% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. REGN: 33.05 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: -0.65 Max: 1948.5
Current: 33.05
-108.7
1948.5
EV-to-EBITDA 30.52
REGN's EV-to-EBITDA is ranked lower than
64% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. REGN: 30.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: -1.15 Max: 387.4
Current: 30.52
-141.9
387.4
Shiller PE Ratio 204.93
REGN's Shiller PE Ratio is ranked lower than
92% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. REGN: 204.93 )
Ranked among companies with meaningful Shiller PE Ratio only.
REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 166.72  Med: 519.34 Max: 4161.1
Current: 204.93
166.72
4161.1
Current Ratio 2.80
REGN's Current Ratio is ranked lower than
66% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. REGN: 2.80 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.63 Max: 55.65
Current: 2.8
2.17
55.65
Quick Ratio 2.45
REGN's Quick Ratio is ranked lower than
67% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. REGN: 2.45 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.4 Max: 55.65
Current: 2.45
2.17
55.65
Days Inventory 491.19
REGN's Days Inventory is ranked lower than
89% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. REGN: 491.19 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 97.79  Med: 170.76 Max: 780.78
Current: 491.19
97.79
780.78
Days Sales Outstanding 128.27
REGN's Days Sales Outstanding is ranked lower than
78% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. REGN: 128.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 93.08 Max: 157.07
Current: 128.27
23.13
157.07
Days Payable 190.21
REGN's Days Payable is ranked higher than
79% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. REGN: 190.21 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 131.02  Med: 172.72 Max: 2718.58
Current: 190.21
131.02
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. REGN: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -7.25 Max: -2.1
Current: -2.1
-17.9
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 67.41
REGN's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. REGN: 67.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
REGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.61  Med: 8.22 Max: 157.38
Current: 67.41
1.61
157.38
Price-to-Tangible-Book 9.95
REGN's Price-to-Tangible-Book is ranked lower than
76% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. REGN: 9.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
REGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.33 Max: 22
Current: 9.95
0.84
22
Price-to-Intrinsic-Value-Projected-FCF 5.22
REGN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
65% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. REGN: 5.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
REGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.44  Med: 15.98 Max: 206.31
Current: 5.22
4.44
206.31
Price-to-Median-PS-Value 0.86
REGN's Price-to-Median-PS-Value is ranked higher than
68% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. REGN: 0.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
REGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.01 Max: 4.35
Current: 0.86
0.18
4.35
Price-to-Graham-Number 4.93
REGN's Price-to-Graham-Number is ranked lower than
73% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. REGN: 4.93 )
Ranked among companies with meaningful Price-to-Graham-Number only.
REGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 5.99 Max: 10.19
Current: 4.93
1.33
10.19
Earnings Yield (Greenblatt) % 3.03
REGN's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. REGN: 3.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
REGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 2.3 Max: 24.9
Current: 3.03
0.1
24.9

More Statistics

Revenue (TTM) (Mil) $4,979
EPS (TTM) $ 8.31
Beta1.57
Short Percentage of Float3.93%
52-Week Range $325.35 - 464.40
Shares Outstanding (Mil)106.29

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 5,424 6,026 6,898
EPS ($) 12.74 15.05 19.63
EPS without NRI ($) 12.74 15.05 19.63
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.66%
Dividends per Share ($)
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive P May 24 2017 
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately May 22 2017 
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately May 22 2017 
Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment i May 08 2017 
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination The May 08 2017 
Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Thera May 08 2017 
Regeneron Announces Upcoming Investor Conference Presentations May 05 2017 
Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily May 02 2017 
Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily May 02 2017 
Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accep Apr 28 2017 

More From Other Websites
Regeneron Presents Positive Phase II Data on HoFH Candidate May 25 2017
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene May 25 2017
Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive... May 24 2017
Theravance/Mylan Presents Phase III Data on COPD Candidate May 24 2017
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data May 24 2017
Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with... May 24 2017
Wide-Moat Roche Is Undervalued May 24 2017
Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis May 23 2017
​Sanofi Genzyme takes on world’s top-selling drugs with new approval May 23 2017
Charter's Rutledge, CBS's Moonves among highest-paid CEOs May 23 2017
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis May 23 2017
Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval May 22 2017
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately... May 22 2017
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately... May 22 2017
Regeneron And Sanofi Have A Near-Term FDA Catalyst May 22 2017
ETFs with exposure to Regeneron Pharmaceuticals, Inc. : May 22, 2017 May 22 2017
Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session May 22 2017
These 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop? May 22 2017
Amgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will? May 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)